07Jan 2023
Antibody response, neutralizing potency, and transplacental antibody transfer following SARS‐CoV‐2 infection versus mRNA ‐1273, BNT162b2 COVID19 vaccination in pregnancy

Antibody response, neutralizing potency, and transplacental antibody transfer following SARS‐CoV‐2 infection versus mRNA ‐1273, BNT162b2 COVID19 vaccination in pregnancy

Understanding of the immune response following COVID-19 vaccination in pregnancy is limited by small cohort size and little data on neutralizing antibodies. This was a prospective cohort study comprising patients with PCR-confirmed SARS-CoV-2 infection and patients who received both doses of mRNA COVID-19 vaccine (mRNA-1273, BNT162b2) in pregnancy recruited from two hospitals in Atlanta, Georgia, USA. There was a significant linear decline in maternal and cord blood RBD-IgG and neutralizing antibody titers as the time from vaccination to delivery increased. Those who receive the mRNA COVID-19 vaccine mount an immune response that is equivalent to – if not greater than- those naturally infected by SARS-CoV-2 during pregnancy.

  • #gynaecology - ivf

Like

Save

Share